Novonesis CEO Ester Baiget told CNBC on Monday that GLP-1 medications and dietary supplements could play complementary roles in managing obesity and supporting longer-term health [1]. The biosolutions company is exploring whether microbiome products can help patients on popular GLP-1 medicines, with Baiget stating "We have scientific evidence that [is] going to support the patients [on] GLP-1s feeling better, as a companion during the treatment" [1]. Novonesis is currently studying "a unique cocktail" of pro-, pre- and post-biotics to support patients taking GLP-1s made by Novo Nordisk, including Wegovy and Ozempic [1].
The weight-loss drug market pioneered by Novo Nordisk and Eli Lilly has already reshaped consumer spending across multiple industries [1]. According to a PwC survey of U.K. adults, approximately 70% of GLP-1 users are spending less on snacks, while 40% are spending more on vitamins and supplements [1]. Additionally, more than 80% of respondents who had stopped taking GLP-1 medicines maintained some of the dietary changes they adopted while on treatment [1]. Baiget emphasized strong commercial demand for supplements with proven health benefits, stating "We see that when we prove science with answers, there is a tremendous pull in the market" [1].
The supplement market represents a significant growth opportunity in the context of GLP-1 adoption. The global dietary supplements market was valued at an estimated $209.5 billion in 2025 and is projected to more than double to $431.7 billion by 2033, according to Grand View Research [1]. Growing health awareness is driving demand for supplements and functional foods and drinks containing ingredients such as vitamins and probiotics [1].
CONCLUSION
The GLP-1 weight-loss drug boom is creating a substantial new market opportunity for dietary supplements, with Novonesis positioning microbiome products as complementary treatments. Consumer spending patterns show 40% of GLP-1 users are increasing supplement purchases, while the global supplement market is projected to nearly double from $209.5 billion in 2025 to $431.7 billion by 2033, indicating significant growth potential for companies developing science-backed supplement solutions.